Functional regulation of CIP/KIP CDK Inhibitors

Mong Hong Lee; Ruiying Zhao

doi:10.1201/9781420005400

Functional regulation of CIP/KIP CDK Inhibitors

Mong Hong Lee, Ruiying Zhao

Molecular & Cellular Oncology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Cell cycle deregulation is one of the most frequent sources of tumor development and stems from either the overexpression of positive regulators or underexpression of negative regulators. Positive regulators consist of cyclins and cyclin-dependent kinases (CDKs), and negative regulators consist of CDK inhibitors (CDKIs). There are two families of CDKIs: the INK4 family (consisting of p16 INK4a, p15 INK4b, p18INK4c, and p19INK4d) and the CIP/KIP family (consisting of p21, p27, and p57). CDKIs are a particular focus of cancer research because they can control cell proliferation, and hence serve as rational cancer therapies. In this chapter we discuss the recently discovered molecular regulation of the CIP/KIP family members.

Original language	English (US)
Title of host publication	Inhibitors of Cyclin-Dependent Kinases as Anti-Tumor Agents
Publisher	CRC Press
Pages	29-53
Number of pages	25
ISBN (Electronic)	9781420005400
ISBN (Print)	9780849337741
DOIs	https://doi.org/10.1201/9781420005400
State	Published - Jan 1 2006

ASJC Scopus subject areas

General Chemistry
General Medicine
General Biochemistry, Genetics and Molecular Biology
Pharmacology, Toxicology and Pharmaceutics(all)

Access to Document

10.1201/9781420005400

Cite this

@inbook{ac1d68d967ea4f518f7768e7df3e3ead,

title = "Functional regulation of CIP/KIP CDK Inhibitors",

abstract = "Cell cycle deregulation is one of the most frequent sources of tumor development and stems from either the overexpression of positive regulators or underexpression of negative regulators. Positive regulators consist of cyclins and cyclin-dependent kinases (CDKs), and negative regulators consist of CDK inhibitors (CDKIs). There are two families of CDKIs: the INK4 family (consisting of p16 INK4a, p15 INK4b, p18INK4c, and p19INK4d) and the CIP/KIP family (consisting of p21, p27, and p57). CDKIs are a particular focus of cancer research because they can control cell proliferation, and hence serve as rational cancer therapies. In this chapter we discuss the recently discovered molecular regulation of the CIP/KIP family members.",

author = "Lee, {Mong Hong} and Ruiying Zhao",

year = "2006",

month = jan,

day = "1",

doi = "10.1201/9781420005400",

language = "English (US)",

isbn = "9780849337741",

pages = "29--53",

booktitle = "Inhibitors of Cyclin-Dependent Kinases as Anti-Tumor Agents",

publisher = "CRC Press",

}

TY - CHAP

T1 - Functional regulation of CIP/KIP CDK Inhibitors

AU - Lee, Mong Hong

AU - Zhao, Ruiying

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Cell cycle deregulation is one of the most frequent sources of tumor development and stems from either the overexpression of positive regulators or underexpression of negative regulators. Positive regulators consist of cyclins and cyclin-dependent kinases (CDKs), and negative regulators consist of CDK inhibitors (CDKIs). There are two families of CDKIs: the INK4 family (consisting of p16 INK4a, p15 INK4b, p18INK4c, and p19INK4d) and the CIP/KIP family (consisting of p21, p27, and p57). CDKIs are a particular focus of cancer research because they can control cell proliferation, and hence serve as rational cancer therapies. In this chapter we discuss the recently discovered molecular regulation of the CIP/KIP family members.

AB - Cell cycle deregulation is one of the most frequent sources of tumor development and stems from either the overexpression of positive regulators or underexpression of negative regulators. Positive regulators consist of cyclins and cyclin-dependent kinases (CDKs), and negative regulators consist of CDK inhibitors (CDKIs). There are two families of CDKIs: the INK4 family (consisting of p16 INK4a, p15 INK4b, p18INK4c, and p19INK4d) and the CIP/KIP family (consisting of p21, p27, and p57). CDKIs are a particular focus of cancer research because they can control cell proliferation, and hence serve as rational cancer therapies. In this chapter we discuss the recently discovered molecular regulation of the CIP/KIP family members.

UR - http://www.scopus.com/inward/record.url?scp=85056033355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056033355&partnerID=8YFLogxK

U2 - 10.1201/9781420005400

DO - 10.1201/9781420005400

M3 - Chapter

AN - SCOPUS:85056033355

SN - 9780849337741

SP - 29

EP - 53

BT - Inhibitors of Cyclin-Dependent Kinases as Anti-Tumor Agents

PB - CRC Press

ER -

Functional regulation of CIP/KIP CDK Inhibitors

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this